Botox Therapeutic

Botox Therapeutic (onabotulinumtoxinA) is a prescription medication made by AbbVie (through Allergan) that uses a highly purified form of botulinum toxin type A for a range of medical conditions. Unlike cosmetic Botox (used for wrinkles), Botox Therapeutic refers specifically to its FDA-approved uses for neurological and muscular disorders, chronic migraines, and bladder conditions.

Without insurance, Botox Therapeutic injections typically cost $1,000–$3,000 per treatment session, and many conditions require treatment every 3–4 months. AbbVie offers the Botox4You patient assistance program for qualifying patients.

How to Afford Botox Therapeutic

• Uninsured patients who meet income requirements may receive free or heavily discounted Botox Therapeutic treatments through AbbVie's Botox4You Patient Assistance Program.
• Commercially insured patients facing high copays can use the Botox Savings Card to reduce out-of-pocket costs.

ClariMeds helps identify and enroll qualifying patients in the right free program for Botox Therapeutic — at no cost to you.

What Does Botox Therapeutic Treat?

Botox Therapeutic is FDA-approved for:

• Chronic migraine prevention — in adults with headaches 15+ days/month (at least 8 of which are migraines); injected every 12 weeks
• Cervical dystonia — abnormal head position and neck pain caused by muscle spasms
• Upper limb spasticity and lower limb spasticity — in adults and children (spasticity from stroke, brain injury, etc.)
• Blepharospasm — involuntary eyelid closure or twitching
• Strabismus — misalignment of the eyes
• Overactive bladder (OAB) with urinary incontinence in adults who have not responded to anticholinergics
• Neurogenic detrusor overactivity (NDO) — bladder muscle overactivity in patients with MS or spinal cord injury
• Primary axillary hyperhidrosis — severe underarm sweating that cannot be managed with antiperspirants

How Botox Therapeutic Works

Botulinum toxin type A blocks the release of acetylcholine — the neurotransmitter that signals muscles to contract and glands to secrete. At the neuromuscular junction, Botox binds to the nerve terminal and prevents synaptic vesicles from fusing with the membrane, stopping acetylcholine release. The result is a localized, reversible chemical denervation: targeted muscles relax or become temporarily paralyzed, and overactive secretions are reduced. In chronic migraine, the mechanism is thought to involve blocking the release of peripheral pain-signaling neuropeptides (like CGRP and substance P) from sensory neurons. Effects last approximately 3–4 months before new nerve terminals form and function is restored.